When considering major players in the CNS (central nervous system) market, Lundbeck is a name that comes to mind. The company's corporate office is located in Copenhagen, Denmark with locations worldwide. This post will take a look at it's current top CNS products and pipeline of potential drugs in trials.
Alzheimer's
Ebixa (memantine) for moderate to advanced AD. For memory and cognition.
Parkinson's Disease
Azilect (rasagiline) to treat signs and symptoms of PD,
Schizophrenia
Abilify Maintena Atypical anti-psychotic for the treatment of Schizophrenia. Extensively used off-label for MDD (major depressive disorder), and Bi-Polar.
Current Trials:
Lu AE58054 as an adjunct to Donpezil. For mild to moderate AD.
NCT01955161 ADAS
Ph 3 Results - 2015
Ph 2 results - 90 mg achieved .004 at 24 weeks.
Brexpiprazole Agitation associated dementia of the Alzheimer's type.
NCT01862640 CMAI
NCT01922258
Ph 3 Results - 2017
Brexpiprazole Many trials for (MDD) Major Depressive Disorder and Schizophrenia as adjunct or mono-therapy.
From the Lunbeck website, there is not an approved drug for either Parkinson's or Alzheimer's disease psychosis that is safe for the elderly unlike Nuplazid is deemed to be. Abilify is black boxed for use in the elderly population experiencing psychosis related to dementia.
Brexpiprazole is currently in a phase 3 trial for agitation associated with dementia of the Alzheimer's type. Within that trial, listed under other measures, is the NPI-NH, and Psychosis Subscale Score. So there will be a readout for hallucinations and delusions along with the primary outcome measure of agitation. Thank you for reading.
Alzheimer's
Ebixa (memantine) for moderate to advanced AD. For memory and cognition.
Parkinson's Disease
Azilect (rasagiline) to treat signs and symptoms of PD,
Schizophrenia
Abilify Maintena Atypical anti-psychotic for the treatment of Schizophrenia. Extensively used off-label for MDD (major depressive disorder), and Bi-Polar.
Current Trials:
Lu AE58054 as an adjunct to Donpezil. For mild to moderate AD.
NCT01955161 ADAS
Ph 3 Results - 2015
Ph 2 results - 90 mg achieved .004 at 24 weeks.
Brexpiprazole Agitation associated dementia of the Alzheimer's type.
NCT01862640 CMAI
NCT01922258
Ph 3 Results - 2017
Brexpiprazole Many trials for (MDD) Major Depressive Disorder and Schizophrenia as adjunct or mono-therapy.
From the Lunbeck website, there is not an approved drug for either Parkinson's or Alzheimer's disease psychosis that is safe for the elderly unlike Nuplazid is deemed to be. Abilify is black boxed for use in the elderly population experiencing psychosis related to dementia.
Brexpiprazole is currently in a phase 3 trial for agitation associated with dementia of the Alzheimer's type. Within that trial, listed under other measures, is the NPI-NH, and Psychosis Subscale Score. So there will be a readout for hallucinations and delusions along with the primary outcome measure of agitation. Thank you for reading.
No comments:
Post a Comment